Impact of CYP2C19 phenotypes on clinical efficacy of stiripentol in Japanese patients with Dravet syndrome.
Sign Up to like & getrecommendations! Published in 2019 at "Therapeutic Drug Monitoring"
DOI: 10.1097/ftd.0000000000000676
Abstract: BACKGROUND Stiripentol is a strong inhibitor of CYP2C19 and CYP3A4. This study compared the effect of stiripentol on the pharmacokinetics of clobazam and N-desmethyl-clobazam (NCLB; an active metabolite of clobazam) between different CYP2C19 phenotypes. We… read more here.
Keywords: japanese patients; cyp2c19 phenotypes; patients dravet; group ... See more keywords